Multi-food oral immunotherapy (OIT) clinical trials

Omalizumab to Accelerate a Symptom-driven Multi-food OIT

This study looks at how a drug called omalizumab can help people with serious food allergies take part in a food desensitisation programme more quickly. It's for people aged 6-25 who are allergic to multiple foods.